ClinicalTrials.Veeva

Menu

Preoperative Oral ImmunoNuTrition to Improve Surgical Outcomes for IBD Patients (PINT)

The University of Alabama at Birmingham logo

The University of Alabama at Birmingham

Status and phase

Withdrawn
Early Phase 1

Conditions

Inflammatory Bowel Diseases

Treatments

Other: Arm B- Standard of Care
Drug: Nestle IMPACT Immunonutrition

Study type

Interventional

Funder types

Other

Identifiers

NCT03333148
IRB -170222002

Details and patient eligibility

About

The central focus of this trial is to understand the effectiveness of Preoperative Immunonutrition (PINT) in improving surgical outcomes for patients with inflammatory bowel disease (IBD). We hypothesize that PINT will reduce post-operative complications in IBD patients undergoing elective surgery with added improvements in length-of-stay (LOS), quality of life (QOL) and patient satisfaction. As a secondary focus, the investigator will aim to better understand the potential mechanism-of-action by which PINT may have its effects through analyses of biomarkers including inflammatory markers, nutritional proteins and the fecal microbiome.

Full description

Inflammatory bowel disease (IBD), which includes Crohn's and Ulcerative Colitis, is a chronic and costly disease of unknown etiology that now affects over 3.1 million people in the United States. Patients with IBD suffer from lifelong malnutrition, pain and bleeding with added risks of cancers, obstructions and fistulas. There is no known cure and the incidence continues to grow. While treatments are usually medical IBD patients will undergo at least one major surgery during their lifetime. Patients also have particularly poor surgical outcomes with high rates of post-operative complications. In an attempt to improve the risk profile of patients and decrease complications, preoperative total parenteral nutrition (TPN) has been used to optimize IBD patients for surgery. While this approach has been successful the cost and morbidities of TPN prohibit its generalized application. Practical strategies that improve surgical outcomes for IBD patients are urgently needed. Improving nutritional deficiencies before an operation may be a practical way to improve post-operative outcomes. The oral administration of preoperative immunonutrition, is an alternative method to improve nutritional states and may have utility in IBD patients who have particularly severe nutritional deficiencies because of disease-specific issues in malabsorption, maldigestion and loss of appetite.

Sex

All

Ages

19+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • ≥19 years of age
  • All races and all genders
  • Confirmed diagnosis and history of IBD
  • ESPEN Nutritional Risk Scores >=3 and the ESPEN Disease Severity sub-score < 3
  • Scheduled for elective surgery via any transabdominal operative approach (i.e. laparoscopic, hand-assisted, robotic, open) with a planned postoperative inpatient stay of at least one night

Exclusion criteria

  • Failure to meet eligibility criteria
  • Patients requiring emergency surgical intervention
  • Patients with an American Society of Anesthesiologist physical status of IV or V
  • Patients requiring hemodialysis
  • Patients with history of myocardial infarction within 6 months
  • Patients with a history of asthma
  • Patients with cirrhosis or a history of liver disease
  • Patients with a present history of dysphagia, pyloric stenosis and esophageal strictures
  • Patients unable to consume liquids orally
  • Patients allergic or with hypersensitivity reactions to any of the components of the Nestlé IMPACT-Advanced Recovery immunonutritional supplement
  • Patients with a history of galactosemia, the inability to metabolize the sugar galactose appropriately
  • Patients with bowel obstructions
  • Patients with history of HIV or of solid-organ transplant
  • Patients who are pregnant or breastfeeding

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

0 participants in 2 patient groups

Arm A - Nestle IMPACT Immunonutrition
Experimental group
Description:
Treatment Arm A (n=146) - Nestlé IMPACT Advanced Recovery:Along with standard of care nutritional therapy patients will be asked to consume 3 cartons/day for 14 days of Nestle IMPACT Advanced Recovery Immunonutrition.
Treatment:
Drug: Nestle IMPACT Immunonutrition
Arm B- Standard of Care
Other group
Description:
No intervention standard of care nutrition (n=146).
Treatment:
Other: Arm B- Standard of Care

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems